Abeona Therapeutics Inc. (ABEO) Stock Rating Reaffirmed by Cantor Fitzgerald
Abeona Therapeutics Inc. (NASDAQ:ABEO)‘s stock had its “buy” rating reaffirmed by investment analysts at Cantor Fitzgerald in a note issued to investors on Friday. They currently have a $21.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price indicates a potential upside of 18.64% from the stock’s previous close.
A number of other analysts also recently issued reports on the company. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Abeona Therapeutics in a research report on Monday, September 18th. Royal Bank Of Canada began coverage on Abeona Therapeutics in a research report on Thursday, September 14th. They set an “outperform” rating and a $23.00 price objective for the company. Maxim Group set a $17.00 price objective on Abeona Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, August 29th. Zacks Investment Research downgraded Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, August 22nd. Finally, BidaskClub downgraded Abeona Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $18.50.
Abeona Therapeutics (NASDAQ:ABEO) opened at 17.70 on Friday. The company’s market cap is $713.08 million. The firm’s 50-day moving average is $13.95 and its 200-day moving average is $8.24. Abeona Therapeutics has a 52-week low of $4.05 and a 52-week high of $18.90.
Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings results on Tuesday, August 15th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.07). Abeona Therapeutics had a negative return on equity of 26.66% and a negative net margin of 2,746.38%. The company had revenue of $0.22 million for the quarter, compared to analysts’ expectations of $0.21 million. On average, equities research analysts anticipate that Abeona Therapeutics will post ($0.68) EPS for the current year.
Several large investors have recently modified their holdings of ABEO. State Street Corp acquired a new stake in shares of Abeona Therapeutics during the 2nd quarter worth about $1,900,000. Northern Trust Corp increased its position in shares of Abeona Therapeutics by 406.3% during the 2nd quarter. Northern Trust Corp now owns 257,668 shares of the biopharmaceutical company’s stock worth $1,649,000 after purchasing an additional 206,775 shares during the last quarter. Highbridge Capital Management LLC increased its position in shares of Abeona Therapeutics by 23.5% during the 1st quarter. Highbridge Capital Management LLC now owns 681,611 shares of the biopharmaceutical company’s stock worth $3,408,000 after purchasing an additional 129,811 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Abeona Therapeutics by 11.2% during the 2nd quarter. Vanguard Group Inc. now owns 1,081,670 shares of the biopharmaceutical company’s stock worth $6,922,000 after purchasing an additional 108,730 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its position in shares of Abeona Therapeutics by 869.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 116,000 shares of the biopharmaceutical company’s stock worth $580,000 after purchasing an additional 104,038 shares during the last quarter. 38.38% of the stock is owned by hedge funds and other institutional investors.
Abeona Therapeutics Company Profile
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).
Receive News & Stock Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related stocks with our FREE daily email newsletter.